智通财经APP讯,长江生命科技(00775)发布2025年中期业绩,该集团取得收入26.06亿港元,同比减少1.14%;公司股东应占亏损1.5亿港元,去年同期则取得溢利100.1万港元;每股亏损1.57港仙。
2024年上半年度与2025年同期比较由盈转亏,乃归因于公司早前计划增加研发投资的决定,相关款项由2024年的7290万港元 提升至2025年的2.353亿港元,亦即公司增加投入1.624亿港元于科研项目以加快进程。
智通财经APP讯,长江生命科技(00775)发布2025年中期业绩,该集团取得收入26.06亿港元,同比减少1.14%;公司股东应占亏损1.5亿港元,去年同期则取得溢利100.1万港元;每股亏损1.57港仙。
2024年上半年度与2025年同期比较由盈转亏,乃归因于公司早前计划增加研发投资的决定,相关款项由2024年的7290万港元 提升至2025年的2.353亿港元,亦即公司增加投入1.624亿港元于科研项目以加快进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.